Christopher Bowden
CIK 1608601 · Chief Medical Officer · last filed 2026-06-10
Christopher Bowden is a Chief Medical Officer who has filed 44 SEC Form 4 insider transactions across 5 companies since 2015. The most recent filing, for BCAX, was dated Jun 10, 2026. Across all open-market trades the lifetime net is −$13.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $571.3K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AGIO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BCAX | Director | — | $16.89 | — | $0 | 2 | 2026-06-10 |
| TCRT | Director | 294 | $2.13 | $626 | $0 | 1 | 2022-06-24 |
| AGIO | Chief Medical Officer | 15,487 | $36.85 | $570.7K | -$13.23M | 35 | 2021-06-22 |
| Alaunos Therapeutics, Inc. (ZIOP) Delisted | Director | 4,167 | $0.87 | $3.6K | $0 | 3 | 2021-05-06 |
| Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Director | — | — | — | $0 | 3 | 2020-05-22 |
Recent Filings
44 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-10 | BCAX | Grant (A) | — | $0 | EDGAR |
| 2025-06-10 | BCAX | Grant (A) | — | $0 | EDGAR |
| 2022-06-24 | TCRT | Grant (A) | +40,000 | $0 | EDGAR |
| 2021-06-22 | AGIO | Mixed | — | -$490.9K | EDGAR |
| 2021-06-21 | AGIO | Mixed | — | -$50.7K | EDGAR |
| 2021-06-11 | AGIO | Mixed | — | -$569.2K | EDGAR |
| 2021-06-09 | AGIO | Mixed | — | -$222.1K | EDGAR |
| 2021-05-06 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Grant (A) | +4,167 | $0 | EDGAR |
| 2021-04-21 | AGIO | Mixed | — | -$342.7K | EDGAR |
| 2021-02-24 | AGIO | Mixed | +2,348 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.